Vanguard Group
RAPP

Vanguard Group’s Rapport Therapeutics RAPP Stock Holding History

Vanguard Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$55.2M Buy
1,817,757
+191,219
+12% +$5.29M ﹤0.01% 2109
2025
Q3 		$48.3M Buy
1,626,538
+519,047
+47% +$9.26M ﹤0.01% 2174
2025
Q2 		$12.6M Sell
1,107,491
-7,933
-0.7% -$84.2K ﹤0.01% 2786
2025
Q1 		$11.2M Buy
1,115,424
+559,951
+101% +$7.27M ﹤0.01% 2783
2024
Q4 		$9.85M Buy
555,473
+48,706
+10% +$1.08M ﹤0.01% 2969
2024
Q3 		$10.4M Buy
506,767
+436,767
+624% +$9.39M ﹤0.01% 2940
2024
Q2 		$1.63M Buy
+70,000
New +$1.62M ﹤0.01% 3628

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group's RAPP Position: Q4 2025 in Review

Vanguard Group increased its Rapport Therapeutics (RAPP) stake by 12% in Q4 2025, buying an estimated $5.29M and bringing the position to 1,817,757 shares worth $55.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2109.

Vanguard Group first reported a position in RAPP in Q2 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Vanguard Group held 1,817,757 shares of Rapport Therapeutics worth $55.2M as of Q4 2025.
  • Vanguard Group bought 191,219 Rapport Therapeutics shares in Q4 2025, an estimated $5.29M.
  • Rapport Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2109 holding.
  • Vanguard Group first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.